The Washington Times

Lilly Alzheimer’s drug trial yields promising sign

Baxter International Inc. also reported some encouraging results in July from its potential Alzheimer’s treatment, Gammagard. The company said a tiny study indicated Gammagard might help stabilize Alzheimer’s for up to three years. Four patients who got the highest dose of Gammagard for three years showed no decline on memory and cognition tests, but a dozen others on different doses or shorter treatment times didn’t fare as well.

That study was too small to prove the treatment works, but a more rigorous one involving 400 patients will end late this year with results expected by early next year.

Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Comments
blog comments powered by Disqus

      Independent voices from the TWT Communities

      Media Migraine

      First over-the-counter column approved for fast and effective relief from even your worst media-induced headache.

      Political Potpourri

      A collection of reader guest articles, thoughts and opinions by Communities writers and breaking news and information.

      Culinary Quest

      Great discoveries in the world of restaurants and chefs fulfill the quest for delicious food and cooking.